Prestige Consumer Healthcare (NYSE:PBH) Stock Price Target Cut by Canaccord Genuity Group

Key Points

• Canaccord Genuity cut its price target on Prestige Consumer Healthcare from $72 to $70 but maintained a Buy rating; the new target implies 61.18% upside from the prior close.
• Analyst views are mixed: the stock has an average rating of Hold and a consensus price target of $67, with one Buy, three Holds, and one Sell rating.
• The company beat quarterly estimates, reporting EPS of $1.13 versus $1.07 expected and revenue of $336.31 million versus $329.14 million expected; revenue rose 22.7% year over year.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) had its price objective dropped by investment analysts at Canaccord Genuity Group from $72.00 to $70.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a "buy" rating on the stock. Canaccord Genuity Group's price target would indicate a potential upside of 61.18% from the company's previous close.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reissued a "sell (d+)" rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 22nd. Zacks Research lowered Prestige Consumer Healthcare from a "strong-buy" rating to a "hold" rating in a research report on Thursday, October 29th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Prestige Consumer Healthcare has an average rating of "Hold" and a consensus price target of $67.00.

Prestige Consumer Healthcare Stock Down 2.0%

Shares of PBH stock traded down $0.89 on Friday, reaching $43.43. 628,739 shares of the company were exchanged, compared to its average volume of 567,253. The company has a market cap of $2.06 billion, a price-to-earnings ratio of 12.17, a PEG ratio of 1.67 and a beta of 0.30. The company has a 50-day moving average of $48.34 and a 200-day moving average of $53.88. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. Prestige Consumer Healthcare has a one year low of $41.77 and a one year high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.07 by $0.06. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%. The company had revenue of $336.31 million during the quarter, compared to the consensus estimate of $329.14 million. During the same period last year, the business posted $1.07 EPS. The firm's revenue for the quarter was up 22.7% compared to the same quarter last year. Analysts anticipate that Prestige Consumer Healthcare will post 4.56 earnings per share for the current year.

Institutional Trading of Prestige Consumer Healthcare

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Prestige Consumer Healthcare in the second quarter valued at approximately $370,187,000. Dimensional Fund Advisors LP increased its position in Prestige Consumer Healthcare by 3.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company's stock worth $158,414,000 after buying an additional 91,710 shares during the last quarter. Rice Hall James & Associates LLC purchased a new stake in Prestige Consumer Healthcare in the second quarter worth $32,602,000. The Manufacturers Life Insurance Company bought a new stake in shares of Prestige Consumer Healthcare in the second quarter valued at $31,135,000. Finally, Bank of America Corp DE bought a new stake in shares of Prestige Consumer Healthcare in the second quarter valued at $26,277,000. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc NYSE: PBH is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company's brands include Dramamine and Bonine for motion-sickness relief; BC and Goody's for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer's Eve for feminine care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.